9 May 2011: Attached are the minutes from the Annual General Meeting in NorDiag held today, 9 May 2011.
 
41 092 028 (59.9%) of the company's outstanding shares were represented in the Annual General Meeting.
 
All resolutions made were in accordance with the recommendations from the Board of Directors and the Nomination Committee.
 
The General Meeting approved the Annual Accounts and the Annual Report for the financial year of 2010, as proposed by the Board of Directors, including the covering of loss.
 
In accordance with the Nomination Committee's proposal, the Chairman of the Board, Robert V. Ahlgren, was re-elected for a term of two years until the Annual General Meeting in 2013 and Mathias Uhlen was re-elected for a term of one year until the Annual General Meeting in 2012.
 
Furthermore, in accordance with the Nomination Committee's proposal, Ann-Kristin Hageløkken was appointed as new Chairperson of the Company's Nomination Committee for a term of two years until the Annual General Meeting in 2013
 
Contact:
 
CEO Mårten Wigstøl            Phone +47 911 65775
CFO Tone Kvåle                 Phone +47 915 19576       
 
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions (instruments and reagents) for sample preparation of DNA from difficult biological samples. DNA diagnostics give more rapid and precise answers, and are the fastest growing field within diagnostics. The Company's sample preparation solutions are today used in connection with STI, tuberculosis, MRSA, respiratory pathogens and viruses on instruments for large and small laboratories. NorDiag was founded in 2003 and has its headquarters in Oslo, Norway. The Company has offices and laboratories in Stockholm, Sweden, in West Chester (PA), USA and in Vienna, Austria. The group has today 41.1 man-labour years. NorDiag is listed on Oslo Stock Exchange with ticker NORD.
 
For further information - www.nordiag.com.

Find the Minutes here

Read the Notice in Norwegian here